XETRA:AFX
Carl Zeiss Meditec AG · XETRA · Healthcare · EUR · FY for 2025
Figures on this page computed 2026-11-08 07:58 UTC
Last close
n/aEUR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
21.7xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
6.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
7.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
1.7%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
Growth is the furthest below its sector's middle: 0.41 against 0.47 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.37x
Its own average over 10 years, 1.63B.
- Profit0.79x
Its own average over 10 years, 178.2M.
- Free cash flow1.27x
Its own average over 10 years, 134.7M.
- Debt2.91x
Its own average over 10 years, 208.6M.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 2.91 times.
The filed years, as a table
10Each line is 100 at 2016-09-30, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-09-30 | 100.0 | 100.0 | 100.0 |
| 2017-09-30 | 109.3 | 136.7 | 105.3 |
| 2018-09-30 | 117.7 | 128.6 | 110.0 |
| 2019-09-30 | 134.1 | 162.5 | 110.0 |
| 2020-09-30 | 122.7 | 124.5 | 110.0 |
| 2021-09-30 | 151.3 | 240.3 | 110.0 |
| 2022-09-30 | 174.8 | 298.9 | 110.0 |
| 2023-09-30 | 192.0 | 295.3 | 110.0 |
| 2024-09-30 | 189.8 | 181.8 | 109.3 |
| 2025-09-30 | 204.7 | 143.6 | 107.7 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- EUR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- EUR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- EUR
Figures behind the shape
Growth
10.8%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate10.8%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
Five-year EPS growth rate3.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
One-year change in net income-21.0%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
Returns on capital
6.7%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity6.7%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets4.1%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
52.8%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin52.8%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin10.0%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin6.3%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin7.7%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
21.7xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings21.7x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
- Computed from the filing for 2025
Price to book1.4x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.4x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
2.35safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.35
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage8.4x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score3.13
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
1.7%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield1.7%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
Payout ratio37.2%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio3.3x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- EUR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.